These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 9018116

  • 1. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity.
    McGuire TF, Sebti SM.
    Oncogene; 1997 Jan 23; 14(3):305-12. PubMed ID: 9018116
    [Abstract] [Full Text] [Related]

  • 2. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
    Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, Greenberg NM, Kreisberg JI.
    Oncogene; 1999 Jul 15; 18(28):4120-30. PubMed ID: 10435593
    [Abstract] [Full Text] [Related]

  • 3. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE, Pfeiffer JR, Lee RJ, Kusewitt DF, Martinez AM, Foutz T, Wilson BS, Oliver JM.
    J Immunol; 1998 Dec 15; 161(12):6733-44. PubMed ID: 9862703
    [Abstract] [Full Text] [Related]

  • 4. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.
    McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM.
    J Biol Chem; 1996 Nov 01; 271(44):27402-7. PubMed ID: 8910319
    [Abstract] [Full Text] [Related]

  • 5. Basic fibroblast growth factor mediated growth inhibition in breast cancer cells is independent of ras signaling pathway.
    Fenig E, Szyper-Kravitz M, Yerushalmi R, Lahav M, Beery E, Wasserman L, Gutman H, Nordenberg J.
    Oncol Rep; 2002 Nov 01; 9(4):875-7. PubMed ID: 12066225
    [Abstract] [Full Text] [Related]

  • 6. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells.
    Song CY, Kim BC, Lee HS.
    Transl Res; 2008 Jan 01; 151(1):27-35. PubMed ID: 18061125
    [Abstract] [Full Text] [Related]

  • 7. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 01; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 8. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 01; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 01; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC, Hamilton AD, Sebti SM.
    Anticancer Drug Des; 1997 Jun 01; 12(4):229-38. PubMed ID: 9199657
    [Abstract] [Full Text] [Related]

  • 11. Inhibitors of Ras farnesylation revert the increased resistance to oxidative stress in K-Ras transformed NIH 3T3 cells.
    Santillo M, Mondola P, Gioielli A, Serù R, Iossa S, Annella T, Vitale M, Bifulco M.
    Biochem Biophys Res Commun; 1996 Dec 24; 229(3):739-45. PubMed ID: 8954966
    [Abstract] [Full Text] [Related]

  • 12. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S, Lodagala DS.
    Acta Pharmacol Sin; 2000 May 24; 21(5):396-404. PubMed ID: 11324435
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.
    Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC.
    Anticancer Res; 2000 May 24; 20(4):2761-71. PubMed ID: 10953355
    [Abstract] [Full Text] [Related]

  • 14. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells.
    Ownby SE, Hohl RJ.
    Lipids; 2002 Feb 24; 37(2):185-92. PubMed ID: 11908910
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.
    van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC, Lokhorst HM.
    Clin Cancer Res; 2003 Nov 15; 9(15):5735-48. PubMed ID: 14654559
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 18. Lovastatin blocks N-ras oncogene-induced neuronal differentiation.
    Mendola CE, Backer JM.
    Cell Growth Differ; 1990 Oct 15; 1(10):499-502. PubMed ID: 2278880
    [Abstract] [Full Text] [Related]

  • 19. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells.
    Xiao L, Lang W.
    Cancer Res; 2000 Jan 15; 60(2):400-8. PubMed ID: 10667594
    [Abstract] [Full Text] [Related]

  • 20. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB, Silverman KC, Jayasuriya H, Kim BM, Amo SE, Wilson FR, Rew DJ, Schaber MD, Bergstrom JD, Koblan KS, Graham SL, Kohl NE, Gibbs JB, Singh SB.
    J Med Chem; 1998 Nov 05; 41(23):4492-501. PubMed ID: 9804689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.